Last updated: February 13, 2026
What is the drug with NDC 43547-0409?
The National Drug Code (NDC) 43547-0409 corresponds to Rituximab (brand name Rituxan), used primarily in treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Overview
Market size and demand:
- The global rituximab market was valued at approximately $6.4 billion in 2022.[1]
- Estimated compound annual growth rate (CAGR): 6-8% over the next five years.
- Growth driven by expanding indications, increased off-label use, and biosimilar entries.
Key competitors:
- MabThera (Rituximab from Roche/Genentech)
- Biosimilars such as Truxima, Ruxience, and Blitzima (approved in various markets)
- Other biologics targeting non-Hodgkin’s lymphoma and autoimmune conditions
Regulatory landscape:
- Original biologic approved in 1997.
- Biosimilar approvals began in 2017 in the U.S.
- Patent cliffs have triggered price reductions and market share shifts.
Pricing Trends and Projections
Current pricing:
- The average wholesale price (AWP) for Rituximab (per 100 mg vial) is approximately $350-$400.
- Treatment courses usually require 375 mg/m² weekly for 4-6 doses, translating to $15,000-$30,000 per course depending on patient size and dose adjustments.
Biosimilar impact:
- Biosimilar entries have reduced Rituximab prices by up to 30-50% in some regions.
- In the U.S., biosimilars like Ruxience and Truxima started at approximately 30-40% lower wholesale prices.
Projected price trends:
- Prices for Rituximab are expected to decline 10-15% annually over the next 2-3 years due to biosimilar competition and market saturation.
- In Europe, pricing pressures have led to reductions of approximately 20% over the last year, with ongoing downward trends.
- In the U.S., prices are projected to stabilize after initial biosimilar discounts, but further declines are possible if additional biosimilars gain approval.
Market Drivers and Risks
Drivers:
- Rising prevalence of autoimmune diseases (e.g., rheumatoid arthritis).
- Expand indications approved by authorities such as the FDA and EMA.
- Increasing adoption of biosimilars and interchangeability policies.
Risks:
- Patent litigation delaying biosimilar entry.
- Healthcare policy changes affecting reimbursement.
- Competitive biologics and targeted therapies (e.g., obinutuzumab, ofatumumab).
Financial Forecasts
| Year |
Estimated Market Size |
Projected Price Drop |
Notes |
| 2023 |
~$6.4 billion |
10% |
Biosimilar approval impact begins |
| 2024 |
~$6.0 billion |
12% |
Increased biosimilar penetration |
| 2025 |
~$5.6 billion |
15% |
Market stabilization, new indications |
| 2026 |
~$5.2 billion |
15% |
Continued growth in autoimmune uses |
Note: Prices reflect wholesale adjustments; actual patient costs may vary based on insurance and negotiated discounts.
Key Takeaways
- NDC 43547-0409 (Rituximab/Rituxan) is a mature biologic with a well-established market.
- The current market shows steady growth driven by increased indications and biosimilar competition.
- Price projections indicate a decline of approximately 10-15% per year over the next three years, largely due to biosimilar penetration.
- Regulatory and patent landscapes significantly influence market dynamics.
- The future of Rituximab pricing hinges on biosimilar approval rates and healthcare policy changes.
FAQs
1. How do biosimilars affect Rituximab’s market pricing?
They typically reduce prices by 30-50%, increasing market competition and driving overall pricing downward.
2. Are there upcoming regulatory changes that could impact Rituximab?
Yes. Biosimilar approvals and interchangeability policies in key markets like the U.S. and EU could accelerate price declines.
3. What are the main indications influencing Rituximab demand?
Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
4. How does the cost of treatment vary globally?
In Europe, prices are generally lower due to price regulation, while in the U.S., higher costs persist, although biosimilar competition is reducing prices.
5. What is the outlook for Rituximab’s market share?
Market share is expected to decrease for the original biologic as biosimilars expand, but demand remains stable due to ongoing clinical use.
References
[1] MarketWatch. "Global Rituximab Market Size, Share & Trends Analysis Report." 2022.
